FMP
Zynerba Pharmaceuticals, Inc.
ZYNE
NASDAQ
Inactive Equity
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
1.3 USD
0.03 (2.31%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Armando Anido MBA
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.zynerba.comexchange
NASDAQ
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
CIK
0001621443
ISIN
US98986X1090
CUSIP
98986X109
Address
80 West Lancaster Avenue
Phone
484 581 7505
Country
US
Employee
25
IPO Date
Aug 5, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ZYNE Financial Summary
CIK
0001621443
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
98986X109
ISIN
US98986X1090
Country
US
Price
1.3
Beta
1.19
Volume Avg.
1.04M
Market Cap
70.12M
Shares
-
52-Week
0.25-1.4
DCF
2.8
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.65
P/B
-
Website
https://www.zynerba.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ZYNE News
It looks like there's no news available.
